BSE · 524564
Gayatri Bioorganics Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Shareholding
As of 2026-06-30
- Promoter21.59%
- Public78.18%
- FII0.01%
- DII0.23%
30,442 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.24× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0. Trading may carry price bands, periodic call auction or higher margins.
- Reported zero revenue in 4 of the last 8 disclosed periods.
Peer comparison
Miscellaneous · ranked #252 of 530 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Ports & Special Economic Zone Ltd. | ₹3,83,402 Cr | 115.16 | 3.99 | 13.32% | 33.06% |
| Eternal Limited | ₹2,99,788 Cr | 1635 | 9.22 | 1.18% | 0.67% |
| BSE Limited | ₹1,43,789 Cr | 182.44 | 21.58 | 37.42% | 51.66% |
| GAIL (India) Ltd. | ₹1,14,170 Cr | 76.83 | 1.28 | 8.51% | 5.34% |
| GMR Airports Limited | ₹1,09,718 Cr | 358.31 | — | -10.6% | 1.19% |
| Mazagon Dock Shipbuilders Ltd. | ₹93,548 Cr | 36.21 | 9.59 | 26.48% | 21.23% |
| One 97 Communications Ltd. | ₹85,371 Cr | 105.25 | 5.33 | 4.55% | 7.25% |
| Meesho Limited | ₹84,197 Cr | — | 19.17 | -28.13% | -8.68% |
| Swiggy Limited | ₹81,680 Cr | — | 4.46 | -22.68% | -18.02% |
| Info Edge (India) Ltd. | ₹80,667 Cr | 142.5 | 2.13 | 3.82% | 0.44% |
| Gayatri Bioorganics Ltd.(this company) | ₹54 Cr | — | — | 3% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashGayatri Bioorganics Ltd. is listed with a market capitalization of Rs 53 Cr. The company had annual revenue of Rs 0 Cr in March 2025 and reported a net loss of Rs 0.7265 Cr in the same period. The promoter holding stands at 21.5855% as of March 2026. The company is currently under GSM surveillance.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no outstanding debt.
- +Promoter pledge is 0% as of March 2026, down from 85.41% in June 2016.
Negatives
- −The company reported no revenue for March 2025.
- −The net profit was negative at -0.7265 Cr in March 2025.
- −The book value per share is negative at -4.7.
- −Return on capital employed (ROCE) is negative at -119.5466%.
- −The company is under GSM surveillance.
Financial performance
Gayatri Bioorganics Ltd. reported no revenue in March 2025, which represents no change from March 2024. The company has reported a net loss for the last five fiscal years, with a loss of Rs 0.7265 Cr in March 2025. Annual EPS was -0.09 in March 2025. Quarterly revenue has been Rs 0 Cr for the last six quarters up to March 2026.
Profitability & returns
The company's profit margin was 0% in March 2025, consistent with no reported revenue. Return on capital employed (ROCE) was -119.5466%. Return on equity (ROE) was 300.5% in March 2025, with a negative book value of -4.7 suggesting accumulated losses exceeding equity.
Balance sheet
Gayatri Bioorganics Ltd. has a debt-to-equity ratio of 0, indicating no debt. The book value per share is negative at -4.7, suggesting that liabilities exceed assets. No specific details about the composition of assets or liabilities are provided in the available data.
Ownership & pledges
Public shareholding is 77.7554%, with DIIs holding 0.6528% and FIIs holding 0.0063%. Over time, promoter pledge percentages have shown variation, reaching as high as 85.41% in June 2016 and decreasing to 0% by March 2026.
Regulatory & surveillance
The company is currently under GSM surveillance, specifically 'GSM 0'. This indicates that the stock has been identified under the Graded Surveillance Measure by regulatory bodies. No further details regarding the specific reasons or implications of this surveillance are provided.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.